#### **Terms and Conditions**

Your access to and use of the information in this e-mail is subject to the following terms and conditions and all applicable laws. By accessing, browsing or copying the information contained herein, you accept, without limitation or qualification, the terms and conditions.

- 1. The information contained in this e-mail is confidential and intended only for the use of the management of Shepherd Center, Inc. and Subsidiaries (the Center) and should not be altered. This email was created June 17, 2025 and Bennett Thrasher LLP will maintain a duplicate copy pursuant to our data retention policies. Additional copies may be requested by reference to its unique identification number 09817.
- 2. With regard to the electronic dissemination of consolidated financial statements, including financial statements published electronically on your (or any other) Internet website, you understand that electronic sites are a means to distribute information and, therefore, we are not required to read the information contained in those sites or to consider the consistency of other information in the electronic site with the original document.
- 3. If you intend to publish the information in this e-mail on the Internet, the information should be published in its entirety and we recommend that "distinct boundaries" should be established around the information so that users are warned whenever they enter or leave pages containing information copied from this e-mail using the following language:

#### Entry Warning:

"You are now accessing the Center's 2025 and 2024 consolidated financial statements and auditors' report. An audit does not provide assurance on the maintenance and integrity of this website or whether changes may have occurred to the consolidated financial statements or auditors' report since first published. These matters are the responsibility of management, but no control procedures can provide absolute assurance in this area."

#### Leave Warning:

"You are now leaving the Center's 2025 and 2024 consolidated financial statements and auditors' report."

4. You are not permitted to copy or distribute this information if you are not the intended recipient named above or the agent of the intended recipient authorized to receive this information. If you received this communication in error, please notify us immediately by telephone collect and delete this e-mail.

Bennett Thrasher LLP Riverwood 200 3300 Riverwood Parkway Suite 700 Atlanta, Georgia 30339

General: 770-396-2200 Fax: 770-390-0394

#### **Consolidated Financial Statements**

March 31, 2025 and 2024



## Table of Contents **March 31, 2025 and 2024**

	Page
Independent Auditor's Report	1
Audited Consolidated Financial Statements:	
Consolidated Statements of Financial Position	4
Consolidated Statements of Operations	5
Consolidated Statements of Changes in Net Assets	6
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8
Supplemental Information:	
Schedule of Expenditures of Federal Awards	28
Notes to Schedule of Expenditures of Federal Awards	30
Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements	
Performed in Accordance with Government Auditing Standards	31
Independent Auditor's Report on Compliance for the Major Federal Program and on Internal Control Over Compliance Required by the Uniform Guidance	33
Schedule of Findings and Questioned Costs	36
Schedule of Prior Audit Findings	37



#### **Independent Auditor's Report**

To the Members of Shepherd Center, Inc. and Subsidiaries

#### **Opinion**

We have audited the accompanying consolidated financial statements of Shepherd Center, Inc. and Subsidiaries (collectively, the Center), which comprise the consolidated statements of financial position as of March 31, 2025 and 2024, and the related consolidated statements of operations, changes in net assets and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Shepherd Center, Inc. and Subsidiaries as of March 31, 2025 and 2024, and the changes in net assets and cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Shepherd Center, Inc. and Subsidiaries and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Shepherd Center, Inc. and Subsidiaries ability to continue as a going concern within one year after the date that the financial statements are available to be issued.



#### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted auditing standards and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with generally accepted auditing standards and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit
  procedures that are appropriate in the circumstances, but not for the purpose of expressing an
  opinion on the effectiveness of Shepherd Center, Inc. and Subsidiaries internal control.
  Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Shepherd Center, Inc. and Subsidiaries ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.



#### Other Matters

#### Other Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended March 31, 2025, as required by *Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

#### Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated June 12, 2025 on our consideration of the Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Center's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control over financial reporting and compliance.

Atlanta, Georgia June 12, 2025

Bennett Musher LLP

## **Consolidated Statements of Financial Position March 31, 2025 and 2024**

	2025	2024
Assets		
Current assets:		
Cash and cash equivalents	\$ 75,141,383	\$ 60,032,254
Patient accounts receivable, less allowance for doubtful		
accounts of \$3,604,821 in 2025 and \$2,885,268 in 2024	83,567,434	94,064,853
Current portion of contributions receivable	34,685,136	42,597,986
Other current assets	12,950,549	14,246,996
Total current assets	206,344,502	210,942,089
Investments	460,830,842	448,811,631
Assets limited as to use	5,662,991	5,144,279
Property and equipment, at cost less accumulated depreciation	360,135,576	268,988,696
Contributions receivable, less current portion and discount of		
\$9,921,920 in 2025 and \$12,429,301 in 2024	63,822,201	84,203,362
Other assets	10,155,684	12,095,542
Total assets	\$ 1,106,951,796	\$ 1,030,185,599
Liabilities and Net Assets		
Current liabilities:		
Current portion of long-term debt	\$ 2,800,000	\$ 2,700,000
Accounts payable	16,280,995	21,262,881
Accrued compensation and expenses	25,211,606	25,440,792
Deferred revenue and other liabilities	2,653,986	2,750,129
Total current liabilities	46,946,587	52,153,802
Annuities payable	5,579,363	5,622,795
Long-term debt, less current portion and unamortized	- / /	- 7- 7
bond issuance costs	104,272,297	52,393,486
Total liabilities	156,798,247	110,170,083
Net assets:		
Without donor restrictions	662,157,993	617,874,584
With donor restrictions	287,995,556	302,140,932
Total net assets	950,153,549	920,015,516
Total liabilities and net assets	\$ 1,106,951,796	\$ 1,030,185,599

#### Consolidated Statements of Operations For the Years Ended March 31, 2025 and 2024

	2025	2024
Revenues, gains and other support without donor restrictions:		
Patient service revenue, net of contractual allowances and discounts	\$ 281,359,016	\$ 272,104,390
Other revenue	43,106,297	39,207,426
Investment income including realized gain on investments	7,257,918	10,458,063
Unrealized gain on investments	5,411,348	40,541,854
Total revenues, gains and other support without donor restrictions, net	337,134,579	362,311,733
Expenses:		
Salaries	143,194,353	136,563,986
Payroll taxes and employee benefits	33,617,825	33,178,527
Patient, pharmacy and office supplies	86,568,037	78,030,423
Purchased services	38,604,650	35,363,166
Depreciation and amortization	14,704,814	11,609,422
Interest	2,462,221	1,947,505
Other	15,167,911	12,572,159
Total expenses	334,319,811	309,265,188
Excess of revenues, gains and other support over expenses	2,814,768	53,046,545
Contributions of property and equipment	88,622	123,696
Net assets released from restrictions, used for purchase		
of property and equipment	41,380,019	101,523,297
Increase in net assets without donor restrictions	\$ 44,283,409	\$ 154,693,538

### **Consolidated Statements of Changes in Net Assets For the Years Ended March 31, 2025 and 2024**

		2025	2024
Net assets without donor restrictions:			
Excess of revenues, gains and other support over expenses	\$	2,814,768	\$ 53,046,545
Contributions of property and equipment		88,622	123,696
Net assets released from restrictions, used for purchase of			
property and equipment		41,380,019	 101,523,297
Increase in net assets without donor restrictions		44,283,409	 154,693,538
Net assets with donor restrictions:			
Contributions		35,729,137	30,783,913
Investment income including realized gain on investments		5,107,750	5,161,490
Unrealized gain on investments		1,724,547	20,133,105
Change in charitable gift annuities		(392,081)	(396,067)
Net assets released from restrictions, used for operations		(14,934,710)	(10,974,664)
Net assets released from restrictions, used for purchase of			
property and equipment		(41,380,019)	 (101,523,297)
Decrease in net assets with donor restrictions		(14,145,376)	 (56,815,520)
Increase in net assets		30,138,033	97,878,018
Net assets, beginning of year		920,015,516	 822,137,498
Net assets, end of year	<u>\$</u>	950,153,549	\$ 920,015,516

#### Consolidated Statements of Cash Flows For the Years Ended March 31, 2025 and 2024

		2025		2024
Cash flows from operating activities:				
Change in net assets	\$	30,138,033	\$	97,878,018
Adjustments to reconcile change in net assets to net				
cash provided by operating activities:				
Net unrealized gain on investments		(7,135,895)		(60,674,959)
Non-operating restricted contributions		(35,729,137)		(30,783,913)
Net realized gains on investments		(1,411,637)		(5,630,977)
Bad debt expense		3,676,997		2,504,039
Depreciation and amortization		14,704,814		11,609,422
Non-operating interest expense		178,811		12,484
Changes in operating assets and liabilities:				
Patient accounts receivable, net of bad debt expense		6,820,422		(15,927,830)
Other assets		968,057		(1,134,846)
Accounts payable and other liabilities		(4,606,130)		6,819,759
Accrued compensation and expenses		(229,186)		1,415,809
Deferred revenue		(96,143)	_	1,923,695
Net cash provided by operating activities		7,279,006		8,010,701
Cash flows from investing activities:				
Purchases of property and equipment		(103,583,446)		(127,790,115)
Purchases of investments		(64,580,423)		(186,510,616)
Proceeds from sale of investments		60,590,032	_	227,040,879
Net cash used in investing activities		(107,573,837)		(87,259,852)
Cash flows from financing activities:				
Proceeds from restricted contributions		64,023,148		50,190,676
Proceeds of long-term debt		54,500,000		15,000,000
Payment of long-term debt		(2,700,000)		(2,600,000)
Deferred financing costs		-		(619,292)
New annuities and payments on annuities, net		(419,188)		(468,371)
Net cash provided by financing activities		115,403,960		61,503,013
Net increase (decrease) in cash and cash equivalents		15,109,129		(17,746,138)
Cash and cash equivalents at beginning of year		60,032,254		77,778,392
Cash and cash equivalents at end of year	<u>\$</u>	75,141,383	\$	60,032,254
Supplemental Disclosure of Cash Flow Information				
Cash paid for interest	<u>\$</u>	2,128,151	\$	1,927,527

Notes to Consolidated Financial Statements March 31, 2025 and 2024

#### Note 1: Description of Organization and Summary of Significant Accounting Policies

#### **Principles of Consolidation**

The accompanying consolidated financial statements include the accounts of Shepherd Center, Inc. (Shepherd) and its wholly owned subsidiaries, SSC Affiliates, Inc. (SSC) and Shepherd Center Foundation, Inc. (Foundation) (collectively, the Center). All significant intercompany accounts and transactions have been eliminated.

#### **Description of Organization**

Shepherd is a private not-for-profit hospital in Atlanta providing acute and rehabilitative care primarily to patients with traumatic spinal cord injuries and disease, acquired brain injury, multiple sclerosis and other neuromuscular disease. Shepherd was incorporated under the laws of the state of Georgia on April 21, 1975. SSC conducts a pharmacy and medical supply sales practice at the Center's premises. SSC was incorporated under the laws of the state of Georgia on November 16, 1990. Foundation raises funding for Shepherd by seeking potential donors and conducting fundraising activities in the community. Foundation was incorporated under the laws of the state of Georgia on May 26, 2004 and remained dormant until April 1, 2005.

#### **Use of Estimates in Consolidated Financial Statements**

The preparation of consolidated financial statements in conformity with generally accepted accounting principles (GAAP) in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### **Net Patient Service Revenue**

Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered, after contractual adjustments. Patient accounts receivable include charges for amounts due from Medicare, Medicaid, pending Medicaid benefits, other third-party payors and patients (see Note 15). Contractual adjustments represent the differences between amounts billed as patient service revenue and amounts contracted with third-party payors and are accrued on an estimated basis in the period in which the related services are rendered and adjusted in future periods as final settlements are determined. Contractual adjustments are included in the determination of net patient service revenue as reported in the accompanying consolidated statements of operations before the provision for doubtful accounts. Deferred revenue represents amounts invoiced or collected prior to having completed performance of service obligations.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and, therefore, have been combined into a single performance obligation for each contract. The Center recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. For inpatient treatment, the Center recognizes revenue equally over the patient stay on a daily basis. For outpatient treatment, the Center recognizes revenue equally over the number of treatments provided in a single episode of care. The Center has minimal unsatisfied performance obligations at the end of the reporting period as patients are typically under no obligation to remain admitted to a facility or program.

Patients and third-party payors are billed within several days of the service being performed or the patient being discharged. Payments are due based on contract terms. As the period between the time of service and time of payment is typically one year or less, the Center elected the practical expedient and did not adjust for the effects of a significant financing component.

The Center grants credit without collateral to its patients, most of whom are insured under third-party payor agreements. Patient accounts receivable are reported at their net realizable value from third-party payors, patients and others for services rendered. Allowances are provided for third-party payors based on estimated reimbursement rates. Allowances are also provided for doubtful accounts based on an estimate of uncollectible accounts. Write-off of uncollectible accounts is determined on a case-by-case basis after a review of the circumstances surrounding the individual patient accounts.

#### **Charity Care**

The Center provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. Because the Center does not pursue collection of amounts determined to qualify as charity care, such amounts are not reported as patient service revenue or patient accounts receivable (see Note 12).

#### **Cash and Cash Equivalents**

Cash and cash equivalents consist of cash in banks and highly liquid temporary investments with initial maturities of ninety days or less. The Center routinely invests its surplus operating funds in money market accounts and highly liquid U.S. government and agency obligations. The Center believes it mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions.

#### **Investments**

Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value in the consolidated statements of financial position. Investment income or loss (including realized gains and losses on investments, interest and dividends and unrealized gains (losses) on marketable equity securities) is reported net of external and direct internal investment expenses and is included in the excess of revenues, gains and other support over expenses unless the income or loss is restricted by donor or law. Unrealized gains and losses on all other investments are excluded from the excess of revenues, gains and other support over expenses and are included in the changes in net assets with donor restrictions.

#### **Property and Equipment**

Property and equipment acquisitions are recorded at cost, net of accumulated depreciation. Depreciation is provided over the estimated useful life of each class of depreciable assets and is computed using the straight-line method. Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized as a component of the costs of acquiring those assets. A summary of the estimated useful lives of the various asset classes is as follows:

Land improvements	5 to 15 years
Building	5 to 40 years
Building services equipment	5 to 27 years
Fixed equipment	5 to 20 years
Major movable equipment	3 to 20 years

Gifts of long-lived assets such as land, buildings, or equipment are reported as support without donor restrictions, unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as support with donor restrictions. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

#### **Impairment of Long-Lived Assets**

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When indicators of impairment are present, management evaluates the carrying amount of such assets in relation to the operating performance and future estimated undiscounted net cash flows expected to be generated by the assets or underlying operations. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. The assessment of the recoverability of assets will be impacted if estimated future operating cash flows are not achieved. In the opinion of management, no long-lived assets were impaired as of March 31, 2025 or 2024.

#### **Inventory**

Inventories of pharmaceuticals, supplies and equipment are valued at the lower of cost (as principally determined on the first-in, first-out method) or market.

#### **Other Assets**

Other assets primarily consist of costs incurred related to the development and integration of internal use software pursuant to a right of use contract with an unrelated healthcare provider. The costs are amortized over the related contract period. The amortizable life is continually monitored for any situation where the estimated useful life of the capitalized costs would be shorter than the amortization period.

#### **Deferred Certificate and Bond Issuance Costs**

Certificate and bond issuance costs were paid to a financial institution for structuring financing arrangements (see Note 8). These issuance costs are being amortized over the related debt term of 5 to 30 years. Interest expense includes amortization of certificate and bond issuance costs of \$178,811 and \$178,703 in 2025 and 2024, respectively.

The unamortized portions of the certificate and bond issuance costs are presented as other assets and a reduction to long-term debt in the accompanying consolidated statements of financial position. The unamortized bond issuance costs totaled \$577,803 and \$756,614 at March 31, 2025 and 2024, respectively.

#### **Fair Value of Financial Instruments**

The following methods and assumptions were used by the Center in estimating the fair value of its financial instruments:

<u>Cash and cash equivalents:</u> The carrying amount reported in the consolidated statements of financial position for cash and cash equivalents approximates its fair value.

<u>Investments</u>: Fair value, which are the amounts reported in the consolidated statements of financial position, are based on quoted market prices, if available, or estimated using quoted market prices for similar securities.

<u>Long-term debt:</u> The fair value of the Center's long-term debt is estimated to approximate its carrying value as a result of the debt's variable interest rate.

#### **Net Assets**

To ensure observance of limitations and restrictions placed on the use of resources available to the Center, the resources are classified for accounting and reporting purposes into categories established according to their nature and purpose. The assets, liabilities, and net assets of the Center are reported as follows:

- Net Assets Without Donor Restrictions Net assets available for use in general operations and not subject to donor-imposed restrictions.
- Net Assets With Donor Restrictions Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

#### **Endowment Funds**

The Center's endowment funds consist of funds established for a variety of purposes (see Note 9). The endowment funds include only donor-restricted endowments. As required by GAAP, net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

#### **Interpretation of Relevant Law Related to Endowment Funds**

The Center's Board of Directors has interpreted Georgia's adoption of the Uniform Prudent Management of Institutional Funds Act (UPMIFA) as requiring the preservation of the purchasing power of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. Because of this, the Center classifies the original value of gifts (initial or subsequent) donated, as well as any gains or other net income generated and potentially available for expenditure, as net assets with donor restrictions in accordance with the purpose established by the donor or until appropriated by the Board of Directors for endowments whose use is without donor restrictions.

#### **Investment and Spending Policies of Endowment Funds**

The Center has established prudent investment and spending policies related to the management of endowment funds and related amounts available for expenditure. These policies have been established and are continually reviewed and updated by the Center's Finance & Investment Committee and Board of Directors. With regard to investments, the Committee takes into account the need to preserve the donor principal, the purposes for which the fund was established, overall economic conditions (to include the effects of inflation and deflation), the expected total return from income as well as possible appreciation from investments, and other resources of the Center. The Center from time to time may also employ an outside investment consultant who assists with the overall asset allocation, investment manager selection, and monitoring and reporting of investment results. The Center's policies are set to achieve a return of at least 5% over inflation in an appropriately diversified portfolio over the long-term, and further allows for spending up to 10% of available earnings in a given year if the endowment earnings are greater than 10% of the principal balance, limited to 4% of the total principal and earnings. In so doing, the goal is to carefully manage the endowment funds such that the principal is preserved and earnings are available in most years for the appropriate purpose. Other goals of spending less than anticipated earnings are allowing for reasonable inflationary growth and helping to cushion against reasonable downturns in the economy. It is also understood that these assumptions and allocations may be revised from time to time as circumstances dictate, so that the Center may continually manage these assets in a prudent manner in accordance with UPMIFA.

#### **Excess of Revenues over Expenses**

The consolidated statements of operations include (deficit) excess of revenues, gains and other support over expenses. Changes in net assets with donor restrictions, which are excluded from (deficit) excess of revenues, gains and other support over expenses, consistent with industry practice, include unrealized gains and losses on investments other than trading securities, marketable equity securities, and contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for the purposes of acquiring such assets).

#### **Donor-Restricted Contributions**

Contributions (including unconditional promises to give, i.e., pledges) are recorded in the year they are received or pledged, with allowances provided for pledges estimated to be uncollectible. Unconditional pledges are recorded at the present value of their estimated future cash flows. The discounts on those amounts are computed using prevailing interest rates applicable to the years in which the promises are received. Amortization of the discounts is included in contributions in the accompanying consolidated statements of changes in net assets. The gifts are reported as contributions with donor restrictions if they are received with donor stipulations or time restrictions that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restrictions are accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the consolidated statements of operations as net assets released from restrictions.

#### **Contributed Services**

A substantial number of volunteers have donated significant amounts of their time to the Center and its various programs; however, these donated services are not reflected in the consolidated financial statements since these services do not meet the criteria for recognition as contributed services.

#### **Income Taxes**

Shepherd and Foundation have both been granted tax-exempt status under Section 501(a) of the Internal Revenue Code (the Code) as organizations described in Section 501(c)(3) whereby only unrelated business income, as defined by Section 512(a)(1) of the Code, is subject to federal income tax. Shepherd and Foundation had no significant unrelated business taxable income during 2025 and 2024; accordingly, no provision or benefit for income taxes has been included in the accompanying consolidated financial statements.

SSC is subject to federal and state income taxes, the balances of which were not material for the years ended March 31, 2025 and 2024.

The provisions of accounting standards for income taxes require that a tax position be recognized or derecognized based on a 'more-likely-than-not' threshold. This applies to positions taken or expected to be taken in a tax return. The Center does not believe its consolidated financial statements include any material uncertain tax positions. The Center is no longer subject to federal or state income tax examinations by tax authorities for calendar years before 2021.

#### **Vacation and Earned Time Off**

Vacation and earned time off benefits are accrued as earned by employees. At March 31, 2025 and 2024, the accrual for vacation and earned time off benefits was approximately \$8,940,000 and \$8,724,000, respectively, and is included as a component of accrued compensation and expenses in the accompanying consolidated statements of financial position.

#### **Self-Insurance**

The Center has a self-insured health plan for medical coverage provided to employees. The Center has purchased stop-loss insurance in order to limit its exposure for large claims that exceed a certain threshold. This coverage will reimburse the Center for claims incurred in excess of \$250,000 per covered person in calendar year 2025 and 2024. In addition, the Center has a self-insured worker's compensation plan, with losses accrued based on estimates of the aggregate liability for uninsured claims incurred using certain actuarial assumptions followed in the insurance industry. At March 31, 2025 and 2024, the accrual for self-insured plans was approximately \$2,627,000 and \$3,751,000, respectively, and is included as a component of accrued compensation and expenses in the accompanying consolidated statements of financial position.

The Center has a self-insured health plan for dental and short-term disability coverage provided to employees. At March 31, 2025 and 2024, the accrual for the self-insured plans totaled approximately \$411,000 and \$417,000, respectively, and is included as a component of accrued compensation and expenses in the accompanying consolidated statements of financial position.

#### **Insurance Claims and Related Insurance Recoveries**

The Center evaluates its exposure to losses arising from claims and, if necessary, recognizes a liability separate from any related anticipated insurance recoveries. The liability, if any, is not presented net of anticipated insurance recoveries. There were no material claims liabilities or related insurance recoveries recorded as of March 31, 2025 and 2024.

#### Reclassifications

Certain prior year amounts have been reclassified to conform to current year presentation. The reclassifications had no effect on previously reported results of operations or net assets

#### Note 2: Liquidity and Availability

Unrestricted financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, are comprised of the following as of March 31, 2025 and 2024:

	2025	2024
Unrestricted cash, cash equivalents and investments Patient accounts receivable, net	\$ 340,654,643 83,567,434	\$ 327,631,506 94,064,853
1 attent accounts receivable, net	\$ 424,222,077	\$ 421,696,359
	\$\frac{1}{4}\frac{1}{4	\$ <del>1</del> 21,070,337

The Center's investments are highly liquid, typically invested in mutual funds and thus available in a very short timeframe. Given this, the amounts shown above are not limited to simply cash, cash equivalents, or investments with a maturity less than one year. In addition, the Center anticipates collecting sufficient patient service revenue to cover general expenditures not covered by donor-restricted resources.

The Center receives significant contributions both with and without donor restrictions to be used in accordance with the associated donor-imposed restrictions. The Center also receives gifts to establish donor-restricted endowments that will exist in perpetuity. Income from donor-restricted endowments is restricted for specific purposes, with the exception of the amounts available for general use. Donor-restricted endowment funds are not available for general expenditure.

Finally, as part of the Center's liquidity management, the Center invests cash in excess of daily requirements in short-term investments and money market funds.

#### Note 3: Assets Limited as to Use

Assets limited as to use are comprised of a supplemental deferred compensation plan and consisted of mutual funds stated at fair value of \$5,662,991 and \$5,144,279 at March 31, 2025 and 2024, respectively.

#### **Note 4: Cash and Investments**

#### Fair Value Measurement

The Center defines fair value as the price that would be received from selling an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date.

When determining fair value, the Center uses various valuation approaches. The accounting standards establish a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Center.

Unobservable inputs reflect the Center's assumptions about the inputs that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.

The fair value hierarchy is categorized into three levels based on the inputs as follows:

**Level 1** - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Center has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 securities. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.

Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The availability of valuation techniques and observable inputs can vary from security to security and is affected by a wide variety of factors, including the type of security, whether the security is new and not yet established in the marketplace, and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Those estimated values do not necessarily represent the amounts that may be ultimately realized due to the occurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of valuation, those estimated values may be materially higher or lower than the values that would have been used had a ready market for the securities existed. Accordingly, the degree of judgment exercised by the Center in determining fair value is greatest for securities categorized in Level 3. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety is determined by the lowest level input that is significant to the fair value measurement.

Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Center's own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Center uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the ability to observe prices and inputs may be reduced for many securities. This condition could cause a security to be reclassified to a lower level within the fair value hierarchy.

#### **Valuation Techniques**

Investments in exchange traded funds, U.S. Government securities, corporate bonds, and mutual funds are valued at quoted market prices.

The Center's investments recorded at fair value have been categorized based upon a fair value hierarchy. The measurements of the fair values of the Center's investments in marketable securities are based on Level 1 and 2 inputs as of March 31, 2025 and 2024.

Investments at fair value at March 31, 2025 and 2024 are comprised of the following:

	2025	2024
Fair value investments:		
Exchange traded funds	\$ 732,997	\$ 5,395,353
U.S. Government securities	14,958,805	25,377,130
Corporate bonds	12,972,645	7,132,851
Mutual funds:		
Equity funds	338,206,164	323,310,298
Fixed income funds	93,960,231	87,595,999
	460,830,842	448,811,631
Total cash and cash equivalents:	75,141,383	60,032,254
	<u>\$ 535,972,225</u>	\$ 508,843,885

At March 31, 2025 and 2024, Level 2 investments consisted of corporate bonds. All other assets were classified as Level 1 at March 31, 2025 and 2024. There were no assets classified as Level 3 at March 31, 2025 and 2024. Additionally, there were no assets transferred in or out of Level 2 or 3 classifications.

#### **Note 5: Contributions Receivable**

Contributions receivable, net of discounts, at March 31, 2025 and 2024 are comprised of the following:

	2025	2024
Unconditional promises expected to be collected in:		
Less than one year	\$ 34,685,136	\$ 42,597,986
One to five years	63,822,201	84,203,362
	\$ 98,507,337	\$ 126,801,348

There was no allowance for unconditional pledges as of March 31, 2025 and 2024.

Certain pledges receivable with due dates extending beyond one year are discounted using 5% as of March 31, 2025 and 2024.

At March 31, 2025 and 2024, three and two donors accounted for 69% and 75%, respectively, of total contributions receivable.

#### **Note 6: Property and Equipment**

A summary of property and equipment at March 31, 2025 and 2024, is as follows:

	2025	2024
Land	\$ 44,910,980	\$ 44,910,980
Land improvements	5,736,743	1,487,223
Building	342,193,967	121,711,360
Building services equipment	74,030,286	60,770,781
Fixed equipment	4,077,886	3,379,740
Major movable equipment	112,106,827	99,703,279
	583,056,689	331,963,363
Less: accumulated depreciation	(226,289,869)	(214,005,825)
	356,766,820	117,957,538
Construction in progress	3,368,756	151,031,158
	\$ 360,135,576	\$ 268,988,696

Construction in progress at March 31, 2025 and 2024, is primarily related to various Center facility expansion and renovation projects. These projects at March 31, 2025 have an estimated total remaining cost to complete of approximately \$72,000,000, and will be funded by the Pursuing Possible campaign funds and bonds. Capitalized interest is not significant in either 2025 or 2024.

Depreciation expense for the years ended March 31, 2025 and 2024 amounted to \$12,436,566 and \$9,416,965, respectively.

#### **Note 7: COVID-19 Relief**

In response to the COVID-19 Pandemic, medical facilities that accepted Medicare patients received Provider Relief Funds (PRF) from the Department of Health and Human Services (HHS). The Center received PRFs of \$6,478,481 during 2022. Usage of PRFs provided to organizations are reportable to the HHS under a predefined schedule released by the HHS based on when organizations receive the funds. The funds received in 2022 were recognized as other income during 2023 when reported to the HHS and are included as a component of other revenue within the accompanying consolidated statements of operations.

The Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) allows for a refundable tax credit against certain employment taxes equal to 70% of qualified wages an eligible employer pays to employees during the period from January 1, 2021 to June 30, 2021. For each eligible employee, wages of up to \$10,000 per quarter can be counted to determine the amount of the credit. During 2024, the Company recognized \$5,993,030 in other income related to the refundable tax credit.

Laws and regulations concerning government programs, including the Employee Retention Credit (ERC) established by the CARES Act are complex and subject to varying interpretations. Claims made under the CARES Act may also be subject to retroactive audit and review. The Company continues to explore additional ways it can benefit from provisions of the CARES Act, which may include ERC, assuming all qualifying factors have been met.

#### Note 8: Long-Term Debt and Line of Credit

#### **Bonds Payable – Series 2009**

Under a Trust Indenture, dated February 1, 2005, between Development Authority of Fulton County (Issuer) and a commercial bank (Trustee), Development Authority of Fulton County Revenue Bonds (Shepherd Center, Inc. Project), Series 2005 (2005 Bonds) totaling \$56,000,000 were issued on April 19, 2005. The Issuer loaned the net proceeds of the sale of the Bonds to the Center, pursuant to a Loan Agreement, dated February 1, 2005 between the Issuer and the Center to enable the Center to finance the acquisition, construction and equipping of improvements to the Center.

Under a Trust Indenture, dated November 4, 2009, between Development Authority of Fulton County (Issuer) and a commercial bank (Trustee), Development Authority of Fulton County Refunding Revenue Bonds (Shepherd Center, Inc. Project), Series 2009 (2009 Bonds) totaling \$56,000,000 were issued on November 4, 2009. The Issuer loaned the net proceeds of the sale of the 2009 Bonds to the Center, pursuant to a Loan Agreement, dated November 1, 2009, between the Issuer and the Center to enable the Center to use the proceeds of the sale of the 2009 Bonds for the purpose of refunding the 2005 Bonds.

Outstanding borrowings totaled \$38,100,000 and \$40,800,000 at March 31, 2025 and 2024, respectively, which are presented net of unamortized bond issuance costs of \$124,839 and \$137,322, respectively.

The Bonds bear interest at a variable rate set not to exceed 12% per annum (2.97% at March 31, 2025) as determined by the remarketing agent (see below) and interest is paid monthly. The average interest rate during 2025 and 2024 was 3.24% and 3.51%, respectively. Interest expense, which included remarketing fees, letter of credit fees, and amortization of bond issuance costs, totaled \$1,533,510 and \$1,735,510 for 2025 and 2024, respectively.

The Bonds are redeemable at the option of the Center, in whole or in part, at various redemption prices on any interest payment date and have required escalating principal payments due annually beginning in December 2019 and maturing in September 2035. Fiscal year contractual maturities of the Bonds payable at March 31, 2025, are as follows:

Year Ending March 31,

2026	9	2,800,000
2027	ų	2,900,000
2028		3,100,000
2029		3,200,000
2030		3,300,000
2031		3,400,000
2032		3,600,000
2033		3,700,000
2034		3,900,000
2035		4,000,000
2036	_	4,200,000
	<u>\$</u>	38,100,000

In connection with the issuance of the 2009 Bonds, the Center obtained an irrevocable letter of credit in the initial amount of \$56,736,439 from a financial institution (Credit Provider). The letter of credit served as a credit enhancement and as security for the bonds. The letter of credit, which is secured by the Center's revenues, was issued on November 4, 2009. On September 2, 2015, the Center obtained a new letter of credit with another financial institution in the initial amount of \$51,873,315 and simultaneously terminated the existing letter of credit. For the years ended March 31, 2025 and 2024, the Center was subject to an annual fee of 0.50% of the letter of credit amount, payable semi-annually in advance. The letter of credit was scheduled to expire on September 2, 2020. In April 2020, the letter of credit was extended effective September 2, 2020 and expires on September 2, 2025. The balance at March 31, 2025 and 2024 was \$38,100,000 and \$40,800,000, respectively.

In addition, the Center entered into a remarketing agent agreement with a financial institution. The remarketing agent determines the weekly variable interest rate and remarkets all Bonds redeemed at the option of the Bond holders for an annual fee of 0.08% of the weighted average daily principal amount of Bonds outstanding.

#### **Bonds Payable – Series 2022**

Under a Bond Purchase and Loan Agreement (the Loan Agreement), dated December 22, 2022, between Development Authority of Fulton County (Issuer) and a commercial bank (Lender), Development Authority of Fulton County Revenue Bonds (Shepherd Center, Inc. Project), Series 2022 (2022 Bonds) up to \$175,000,000 may be issued pursuant to the Loan Agreement. The Loan Agreement will support the Center in financing the construction and equipping of improvements to the Center.

Outstanding borrowings totaled \$69,550,100 and \$15,050,100 at March 31, 2025 and 2024, respectively. For the years ended March 31, 2025 and 2024, unamortized bond issuance costs were \$452,964 and \$619,292, respectively, and were presented net of outstanding borrowings.

The Bonds bear interest at a variable rate set at the Securities Industry and Financial Markets Association (SIFMA) index rate plus 0.711% (3.58% at March 31, 2025) as determined by the remarketing agent (see below) and interest is paid monthly. The average interest rate during 2025 and 2024 was 3.89% and 4.21%, respectively. Interest expense, which included amortization of bond issuance costs, totaled \$884,138 and \$166,219 for 2025 and 2024, respectively.

The Bonds are redeemable at the option of the Center, in whole or in part, at various redemption prices on any interest payment date and mature in December 2027, at which time the Center would be required to either refinance or repay the bonds in full.

#### Line of Credit

The Center maintains an unsecured revolving loan agreement with maximum borrowing capacity of \$20,000,000 through August 31, 2025, at which time the balance, if any, plus accrued interest is due. Outstanding borrowings bear interest at Adjusted Term Secured Overnight Financing Rate (SOFR), which is defined as the sum of the Term SOFR for the period plus a margin of 0.64%. As of March 31, 2025, and 2024, there was no outstanding balance on the line of credit. Interest expense, which included certain legal and commitment fees, totaled \$25,417 and \$25,347 for 2025 and 2024, respectively.

The Center is subject to certain financial and nonfinancial covenants under the various Bond and line of credit agreements. At March 31, 2025, the Center was in compliance with these covenants.

#### **Note 9: Net Assets With Donor Restrictions**

Net assets with donor restrictions, not included in endowment net assets, are restricted for the following purposes at March 31, 2025 and 2024:

	2025	2024
Net Assets With Donor Restrictions - Non-Endowment:		
Pursuing Possible	\$ 105,808,258	\$ 125,593,128
Share Initiative	17,305,421	19,060,402
Research	14,404,592	10,220,725
MS General Fund	9,208,786	6,010,305
Jesse Crawford Research Fund	5,606,653	5,610,148
Shepherd Center Fund	4,243,133	4,082,417
Other Miscellaneous Funds	4,174,889	4,082,629
Charitable Gift Annuity Program	3,601,130	3,555,076
Andee's Army	2,050,355	1,981,058
Animal Therapy Fund	1,515,314	1,469,963
MS Rehab and Wellness Fund	1,487,217	1,627,768
Housing/Transportation Fund	1,352,828	2,822,885
Assistive Technology Fund	1,094,916	1,084,006
Patient Assistance	1,039,815	951,595
Transition Support	1,002,919	966,732
Recreation Therapy	973,793	1,458,121
Chaplaincy Fund	792,502	805,469
Outpatient	702,929	681,278
Capital Projects and Maintenance	643,017	509,226
Vocational Services	571,882	744,650
Education	516,573	37,599
SCI Program	378,422	344,519
Acquired Brain Injury Fund	316,460	308,396
SCI Research Program	269,111	604,375
Prevention Fund	45,737	45,767
Patient Equipment	6,920	6,658
	\$ 179,113,572	<u>\$ 194,664,895</u>

Endowment net assets with donor restrictions are restricted for the following purposes at March 31, 2025:

	Endow	ment Principal	<b>Endowment Earnings</b>		Tota	al Endowment
Charity Care	\$	8,067,309	\$	9,402,903	\$	17,470,212
Recreation Therapy		7,007,919		6,535,092		13,543,011
Assistive Technology		6,959,523		4,585,350		11,544,873
Other Miscellaneous Funds		5,311,196		8,441,695		13,752,891
Patient Equipment		4,776,696		8,849,880		13,626,576
Research		3,605,090		2,746,190		6,351,280
Housing/Transportation		2,380,937		2,251,997		4,632,934
Professional Development		2,160,517		4,256,618		6,417,135
MS Research		1,960,111		2,243,571		4,203,682
Capital Projects and Maintenance		1,684,084		3,827,075		5,511,159
Vocational Services		1,374,207		1,362,274		2,736,481
Noble Learning Resource Center		1,208,704		1,204,700		2,413,404
Outpatient		1,000,000		1,873,914		2,873,914
Injury Prevention Program		709,161		740,419		1,449,580
Advocacy		512,509		520,059		1,032,568
Animal Therapy Fund		336,076		266,429		602,505
Chaplaincy		198,110		209,477		407,587
Wishing Wall		106,016		206,176		312,192
	\$	49,358,165	\$	59,523,819	\$	108,881,984

Endowment net assets with donor restrictions are restricted for the following purposes at March 31, 2024:

	<b>Endowment Principal</b>		<b>Endowment Earnings</b>		Tota	al Endowment
Charity Care	\$	8,065,309	\$	9,409,457	\$	17,474,766
Other Miscellaneous Funds		5,311,196		8,449,913		13,761,109
Patient Equipment		4,650,721		9,012,085		13,662,806
Recreation Therapy		7,001,919		6,543,341		13,545,260
Assistive Technology		5,957,664		4,721,261		10,678,925
Research		3,503,430		2,755,724		6,259,154
Professional Development		2,160,517		4,078,882		6,239,399
Capital Projects and Maintenance		1,684,084		3,618,330		5,302,414
Housing/Transportation		2,380,937		2,253,933		4,634,870
MS Research		1,960,111		2,246,083		4,206,194
Outpatient		1,000,000		1,777,684		2,777,684
Vocational Services		1,374,207		1,363,909		2,738,116
Noble Learning Resource Center		1,208,704		1,206,143		2,414,847
Injury Prevention Program		709,161		741,286		1,450,447
Advocacy		512,509		520,272		1,032,781
Animal Therapy Fund		321,076		265,906		586,982
Chaplaincy		198,110		209,720		407,830
Wishing Wall		106,090		196,363		302,453
	\$	48,105,745	\$	59,370,292	\$	107,476,037

Changes in endowment net assets with donor restrictions for the years ended March 31, 2025 and 2024, are as follows:

	2025	2024
Beginning of the year	\$ 107,476,037	\$ 95,733,515
Contributions	1,250,635	20,250
Investment income	2,316,635	3,007,712
Unrealized gain	1,900,971	12,622,653
Expenditures	(4,062,294)	(3,908,093)
End of the year	<u>\$ 108,881,984</u>	\$ 107,476,037

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original gift. In accordance with GAAP, deficiencies of this nature, should they occur, would be reported as net assets with donor restrictions.

During 2025 and 2024, net assets were released from donor restrictions by incurring expenses, purchasing equipment or completing other capital projects satisfying the restricted purposes in the amounts of \$56,314,729 and \$112,497,961, respectively. The releases generally related to the purposes listed above.

#### **Note 10: Net Patient Service Revenue**

The Center has agreements with third-party payors that provide for payments to the Center at amounts different from its established rates. A summary of the payment arrangements with major third-party payors follows:

Services rendered to Medicare program beneficiaries are paid based on prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic and other factors.

Medicaid inpatient services are paid on a prospective payment system and outpatient services are reimbursed under a cost reimbursement methodology. The Center is reimbursed at a tentative rate with final settlement determined after submission of annual cost reports by the Center and audits thereof by the Medicaid fiscal intermediary.

Patients identified as low-income and that have not been approved for Medicaid benefits are classified as "Medicaid Pending." The Center assists the patients in obtaining these benefits from the Georgia Department of Medical Assistance.

The Center also has entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the Center under these agreements includes prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. With respect to reserves for these agreements, the Center typically reserves a percentage of relevant revenues. The Center has historically provided such reserves in recognition of the complexity of relevant reimbursement regulations, the volatility of related settlement processes, and an increasingly provocative healthcare regulatory environment and believes that such policy provides the Center's routine exposures in this area consistent with industry-specific accounting principles and practices. In any event, the Center's estimates in this area may differ from actual experience, and those differences may be material.

#### **Note 11: Functional Expenses**

The consolidated financial statements report certain categories of expenses that are attributed to more than one program or supporting function. Accordingly, certain costs have been allocated among the programs and supporting services benefited based on what management believes are reasonable methodologies, such as headcount and estimations of time spent within various departments. Expenses that are allocated include food service expense, Shepherd Share bonus, and payroll taxes and benefits. Food service expense is allocated based on the number of patient meals versus employee meals served. The Shepherd Share bonus and payroll taxes and benefits are allocated in each functional area based on salary expense.

Expenses related to providing these services for the year ended March 31, 2025 are as follows:

	Program E	expenses	es Management & General Expenses			
	Health Care Services	Research	Administrative Services	Facilities and Other Expenses	Fundraising	Total
Salaries	\$ 103,157,157	\$ 4,976,675	\$ 28,205,416	\$ 3,850,150	\$ 3,004,955	\$ 143,194,353
Payroll taxes and						
employee benefits	23,992,659	1,151,717	6,842,909	916,892	713,648	33,617,825
Patient, pharmacy and						
office supplies	82,963,736	111,402	2,513,403	824,267	155,229	86,568,037
Purchased services	15,015,006	1,347,433	16,792,238	4,888,962	561,011	38,604,650
Depreciation and						
amortization	-	-	2,268,249	12,436,565	-	14,704,814
Interest	-	-	-	2,462,221	-	2,462,221
Other	5,642,054	284,561	7,808,896	1,127,402	304,998	15,167,911
Total expenses	\$ 230,770,612	\$ 7,871,788	\$ 64,431,111	\$ 26,506,459	\$ 4,739,841	\$ 334,319,811

Expenses related to providing these services for the year ended March 31, 2024 are as follows:

	Program Expenses		Management & 0	General Expenses			
	Health Ca		Research	Administrative Services	Facilities and Other Expenses	Fundraising	Total
Salaries	\$ 98,964	,292	\$ 4,425,540	\$ 26,613,798	\$ 3,429,219	\$ 3,131,137	\$ 136,563,986
Payroll taxes and employee benefits	24,229	.713	1,041,384	6,278,690	851,372	777,368	33,178,527
Patient, pharmacy and	,	, -	7- 7	-, -,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	,,-
office supplies	74,678	,422	39,709	2,524,823	638,298	149,171	78,030,423
Purchased services	14,564	,919	1,697,486	14,677,891	3,975,988	446,882	35,363,166
Depreciation and							
amortization		-	-	2,192,455	9,416,967	-	11,609,422
Interest		-	-	-	1,947,505	-	1,947,505
Other	4,307	,148	295,605	6,795,500	763,006	410,900	12,572,159
Total expenses	\$ 216,744	,494	\$ 7,499,724	\$ 59,083,157	\$ 21,022,355	\$ 4,915,458	\$ 309,265,188

#### **Note 12: Charity Care**

The Center maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone for services and supplies furnished under its charity care policy and the estimated cost of those services and supplies. The following information measures the Center's charity care provided during the years ended March 31, 2025 and 2024:

	2025	2024
Charges foregone, based on established rates	\$ 15,271,925	\$ 12,952,491
Estimated costs and expenses incurred to provide charity care	\$ 5,520,580	\$ 5,086,900

The Center determined estimated costs and expenses incurred to provide charity care by applying the Medicare and Medicaid ratio of costs to charges percentages to charges foregone related to identified charity patients.

In addition to charity care, the Center provides many other services not typically paid for by insurance or government payors. During the years ended March 31, 2025 and 2024, the Center incurred \$18,588,904 and \$15,626,839, respectively, in expenses supporting programs including, but not limited to, recreation therapy, patient equipment, assistive technology, housing, vocational services, research, transition support, the Noble Learning Resource Center, professional development, injury prevention and advocacy.

#### Note 13: Benefit Plan

The Center provides a defined contribution plan for substantially all employees. The amount of employer contribution is determined by the Board of Directors annually. Employees are one hundred percent vested in employer contributions after three full years of service. Amounts charged to expense for the plan were \$4,203,482 and \$4,251,095 in 2025 and 2024, respectively.

#### **Note 14: Commitments and Contingencies**

#### **Industry**

The health care industry is subject to laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Over the past several years, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by health care providers. Violations of these laws and regulations could result in expulsion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Center is in compliance with fraud and abuse statutes as well as other applicable government laws and regulations. The Center has established an Ethics in Business program and has a dedicated compliance officer in order to help ensure compliance with applicable laws and regulations.

#### Litigation

The Center, at times, is involved in litigation arising in the ordinary course of business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on the Center's financial position, change in net assets or cash flows.

#### **Note 15: Concentrations of Credit Risk**

The Center grants credit without collateral to its patients, most of whom participate under third-party payor agreements (see Note 10). The mix of receivables from patients and third-party payors at March 31, 2025 and 2024, is as follows:

	2025	2024
Medicare	6%	8%
Medicaid	9%	4%
Commercial	61%	68%
Workers' compensation	24%	20%
	100%	100%

The mix of gross charges for the years ended March 31, 2025 and 2024 is as follows:

	2025	2024
Medicare	18%	18%
Medicaid	5%	5%
Commercial	58%	60%
Workers' compensation	13%	12%
Other	6%	5%
	100%	100%

At March 31, 2025 and 2024, the Center has cash and cash equivalent balances in major financial institutions which exceed federal depository insurance limits. Management believes that credit risk related to these deposits is minimal. Investment securities are exposed to various risks such as interest rate, market and credit. Market values of securities fluctuate based on the magnitude of changing market conditions; significant changes in market conditions could materially affect portfolio value in the near term.

#### **Note 16: Related Party Transactions**

Contributions from Shepherd board members totaled approximately \$1,651,000 and \$5,821,000 in 2025 and 2024, respectively. Contributions from Foundation board members totaled approximately \$2,643,000 and \$3,219,000 in 2025 and 2024, respectively.

#### **Note 17: Gift Annuities**

The Center enters into agreements with donors in which the donors contribute Annuity Gifts to the Center in exchange for an annuity to be paid to the donor or their designee for a specified period of time. The assets received for an annuity are recorded at fair value at the date of the gift. The liability associated with Annuity Gifts is recorded at present value based on Internal Revenue Service mortality tables and prevailing interest rates. The difference constitutes an increase to net assets with donor restrictions. At March 31, 2025 and 2024, the liability associated with received Annuity Gifts was estimated to be \$5,579,363 and \$5,622,795, respectively.

#### **Note 18: Other Current Assets**

Other current assets as of March 31, 2025 and 2024 consists of the following:

	2025	2024
Inventory (see Note 1)	\$ 5,803,534	\$ 6,855,041
Prepaid expenses	5,296,467	4,975,078
Grant and research receivables	1,717,773	1,487,075
Other current assets	 132,775	 929,802
	\$ 12,950,549	\$ 14,246,996

#### **Note 19: Other Revenue**


Other revenue for the years ended March 31, 2025 and 2024 consists of the following:

	2025	2024
Net assets released from restrictions, used for operations (see Note 1)	\$ 14,934,710	\$ 10,974,664
Contributions without donor restrictions	10,104,965	7,094,556
Employee retention credits	-	5,993,030
Grant income	5,237,803	4,310,656
Retail sales, net	6,882,922	5,523,547
Other	1,815,481	1,706,934
Cafeteria sales	1,781,923	1,687,185
Rebates and incentives	1,849,347	1,674,569
Clinical trials	499,146	242,285
	\$ 43,106,297	\$ 39,207,426

#### **Note 20: Subsequent Events**

The Center has evaluated subsequent events between the consolidated statement of financial position date of March 31, 2025 and the report date, the date the consolidated financial statements were issued, and has concluded all subsequent events requiring recognition or disclosure have been reflected in these consolidated financial statements.

\* \* \* \* \*



#### Schedule of Expenditures of Federal Awards For the Year Ended March 31, 2025

Federal Grantor/Pass-through Grantor/Program or Cluster Title	Assistance Listing Number	Pass-Through Entity Identifying Number	Provided to Subrecipients	Federal Expenditures
Research and Development Cluster				
Department of Health and Human Services				
Administration for Community Living				
Program - ACL National Institute on Disability, Independent Living, and Rehabilitation Research				
Direct Awards:  Rehabilitation Engineering Research Centers	93.433		\$ 286,343	\$ 697,931
Disability and Rehab Research Projects Health and Function	93.433		171,100	366,883
Southeastern Regional Spinal Cord Injury Model Systems	93.433		62,660	523,016
Georgia Model Brain Injury System (GAMBIS)	93.433		28,582	456,525
Total Direct Awards			548,685	2,044,355
Pass-through Awards from:				
Medical University of South Carolina	02.422	422 0002 C002		4.700
Quality Employment Outcomes Throughout the Work Lifecycle Rehabilitation Research & Training Center (RRTC) on Health and Function of People Aging with Physical Disability	93.433 93.433	A22-0082-S002 NHV3GTWSALA7	-	4,788 7,795
Georgia Institute of Technology	73.433	NIIVJGI WJALA/	-	1,193
Developing Evidence-Based Wheelchair Cushion Prescription Using Interface Pressure & Postural Stability Measurements  Kinemo	93.433	EMW9FC8J3HN4	-	3,351
Kinemo: Simplifying Alternative Control to Increase Independence in Mobility & Digital Access for People with Tetraplegia	93.433	VQ6BKLJ1RQX7	-	23,646
Craig Hospital Scale Up Trial of Project WOWii to Increase Exercise Among People with Spinal Cord Injury	93.433	EFCEJ3FDEH77	-	11,133
Total Pass-through Awards				50,713
Total ACL National Institute on Disability, Independent Living, and Rehabilitation Research			548,685	2,095,068
National Institutes of Health				
Program - Child Health and Human Development Extramural Research				
Direct Awards:				
Calibrating Transcutaneous Spinal Stimulation for Spasticity, Pain, an Motor Function of SCI	93.865		4,903	335,622
Intensive Rehabilitation Research Grant Writing Workshop in the US (TIGRR)	93.865		65,431	87,570
Total Direct Awards			70,334	423,192
Pass-through Award from:				
Indiana University	02.052	VIIIO CD TOVIOVIII II 4		160.220
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	YH86RTW2YVJ4		168,230
Total Pass-through Awards				168,230
Total Child Health and Human Development Extramural Research			70,334	591,422
Total Department of Health and Human Services			619,019	2,686,490
Department of Defense Administration for Community Living Program - Military Medical Research & Development				
Direct Award: Expanding Access to mTBI Treatment for Veterans & Service Members with Co-Occuring Substance Use	12.420		\$ 500	\$ 191,851
Total Department of Defense			500	191,851
Total Research & Development Cluster			\$ 619,519	\$ 2,878,341
Total Research & Development Cluster - 28 -			φ 017,517	2,070,371

### Schedule of Expenditures of Federal Awards (Continued) For the Year Ended March 31, 2025

Federal Grantor/Pass-through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity Identifying Number	Provided to Subrecipients	Federal Expenditures
Department of Health and Human Services Administration for Community Living Program - Consolidated Appropriations Act Direct Award: FY23-CFP-Shepherd Center Inc.  Total Department of Health and Human Services	94.493		<u>\$</u>	\$ 458,999 458,999
Department of Agriculture  National Institute of Food and Agriculture  Program - Cooperative Extension Service  Pass-through Award from:  University of Georgia  AgrAbility in Georgia	10.500	NMJHD63STRC5		1,803
Total Department of Agriculture  Department of Transportation  National Highway Traffic Safety Administration  Program - National Priority Safety  Pass-through Award from:  Georgia Governor's Office of Highway Safety  A Safe System Approach to Rural Roads	20.616	VLK3CFUK8N25		1,803
Total Department of Transportation			<del>_</del>	205,187
Total Expenditures of Federal Awards			\$ 619,519	\$ 3,544,330

See independent auditor's report and accompanying notes to schedule of expenditures of federal awards.

#### Notes to Schedule of Expenditures of Federal Awards For the Year Ended March 31, 2025

#### **Note A:** Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of Shepherd Center, Inc. and Subsidiaries (the Center) under programs of the Federal Government for the year ended March 31, 2025. The information in this schedule is presented in accordance with the requirements of *Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the Center, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the Center.

#### **Note B:** Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement.

#### **Note C:** Federal Pass-through Funds

The Center is the subrecipient of federal funds, which have been subject to testing and are reported as expenditures and listed as federal pass-through funds in the accompanying schedule. Federal awards other than these are considered direct.

#### **Note D: Indirect Cost Rate**

The Center has elected not to use the 10-percent de minimis indirect cost rate allowed under the Uniform Guidance.



# Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Directors of Shepherd Center, Inc. and Subsidiaries

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Shepherd Center, Inc. and Subsidiaries (the Center), which comprise the consolidated statement of financial position as of March 31, 2025, and the related consolidated statements of operations, changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements and have issued our report thereon dated June 12, 2025.

#### Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Center's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Center's internal control. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.



#### **Report on Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Center's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

#### **Purpose of this Report**

Blunet Musker LLP

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Center's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Atlanta, Georgia June 12, 2025



### Independent Auditor's Report on Compliance for the Major Federal Program and on Internal Control Over Compliance Required by the Uniform Guidance

To the Board of Directors of Shepherd Center, Inc. and Subsidiaries

#### Report on Compliance for the Major Federal Program

#### Opinion on the Major Federal Program

We have audited Shepherd Center, Inc. and Subsidiaries' (the Center) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on the Center's major federal program for the year ended March 31, 2025. The Center's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on the major federal program for the year ended March 31, 2025.

#### Basis for Opinion on the Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Center and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for the major federal program. Our audit does not provide a legal determination of the Center's compliance with the compliance requirements referred to above.

#### Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Center's federal programs.



#### Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Center's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Center's compliance with the requirements of the major federal program as a whole.

In performing an audit in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Center's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Center's internal control over compliance relevant to the
  audit in order to design audit procedures that are appropriate in the circumstances and to
  test and report on internal control over compliance in accordance with the Uniform
  Guidance, but not for the purpose of expressing an opinion on the effectiveness of the
  Center's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.



#### **Report on Internal Control Over Compliance**

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance Section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Atlanta, Georgia June 12, 2025

Bennett Muchen LLP

### Shepherd Center, Inc. and Subsidiaries

(A Not-for-Profit Organization)

### Schedule of Findings and Questioned Costs For the Year Ended March 31, 2025

#### Section I – Summary of Auditor's Results

#### **Financial Statements**

Type of auditor's report issued: Unmodified.

Internal control over financial reporting:
Material weaknesses identified? No.
Significant deficiencies identified? None reported.

Noncompliance material to financial statements noted? No.

#### **Federal Awards**

Internal control over major programs:

Material weaknesses identified? No.

Significant deficiencies identified? None reported.

Type of auditor's report issued on compliance for all major programs: Unmodified.

Any audit findings disclosed that are required to be reported in accordance with 2 CFR section 200.516(a)? No.

Identification of major federal program:

CFDA Number	Name of Federal Program or Cluster
93.433, 93.853,	
93.865.12.420	Research and Development Cluster

Dollar threshold used to distinguish between type A and type B programs: \$750,000.

Auditee qualified as low-risk auditee? Yes.

#### **Section II – Financial Statement Findings**

No matters were reported.

#### Section III – Federal Award Findings and Questioned Costs

No matters were reported.

#### Schedule of Prior Audit Findings For the Year Ended March 31, 2025

Findings from the year ended March 31, 2024:

None.